Scarica l'app Stockscreener
104.94
2.45%
2.51
Pre-mercato:
104.50
-0.44
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$102.43
Aprire:
$104.2
Volume 24 ore:
729.39K
Relative Volume:
0.71
Capitalizzazione di mercato:
$24.52B
Reddito:
$2.98B
Utile/perdita netta:
$-717.57M
Rapporto P/E:
-35.00
EPS:
-2.9987
Flusso di cassa netto:
$-264.74M
1 W Prestazione:
+2.86%
1M Prestazione:
+12.45%
6M Prestazione:
-5.87%
1 anno Prestazione:
+13.77%
Intervallo 1D:
$103.51
$106.50
Intervallo di 1 settimana:
$99.85
$108.79
Portata 52W:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Confronta BNTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
104.94 | 24.52B | 2.98B | -717.57M | -264.74M | -2.9987 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-01-10 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-11-19 | Iniziato | Berenberg | Buy |
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-14 | Iniziato | Evercore ISI | In-line |
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-05 | Iniziato | Oppenheimer | Perform |
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-17 | Iniziato | Cowen | Market Perform |
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell |
| 2021-05-18 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-08-03 | Ripresa | Berenberg | Buy |
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Downgrade | UBS | Buy → Neutral |
| 2019-11-05 | Iniziato | Wolfe Research | Outperform |
| 2019-11-04 | Iniziato | Berenberg | Buy |
| 2019-11-04 | Iniziato | BofA/Merrill | Buy |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-11-04 | Iniziato | JP Morgan | Overweight |
| 2019-11-04 | Iniziato | SVB Leerink | Outperform |
| 2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech SE ADR [NASDAQ: BNTX] Sees Increase in Stock Value - knoxdaily.com
HRL Shares Experience Surge in Value - knoxdaily.com
Nordson Corp [NDSN] stock for 268,620 USD was sold by Lovass Stephen - knoxdaily.com
Hanesbrands Inc [HBI] Records 200-Day SMA of $6.81 - knoxdaily.com
Ratio Review: Analyzing Regency Centers Corporation (REG)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Metrics Exploration: Understanding MARA Holdings Inc (MARA) Through Ratios - DWinneX
Financial Fitness Check: Examining BioNTech SE ADR (BNTX)’s Key Ratios - DWinneX
The growth track for BioNTech SE ADR (BNTX) has changed recently - Sete News
Financial Health Report: Arthur J. Gallagher & Co (AJG)’s Ratios Tell a Tale - DWinneX
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales - sharewise
A year in review: BioNTech SE ADR (BNTX)’s performance in the last year - uspostnews.com
BioNTech SE ADR (NASDAQ: BNTX) Could Make Significant Gains? - Marketing Sentinel
Investors Could Make -86.23% On NOV Inc (NYSE: NOV) Stock - Marketing Sentinel
Let’s Start With The Stock Forecast For UroGen Pharma Ltd (NASDAQ: URGN) - Marketing Sentinel
Is Murphy Oil Corp (NYSE: MUR) Stock Set To Rise More? - Marketing Sentinel
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
BioNTech SE ADR (BNTX) Stock: A Year of Market Fluctuations - investchronicle.com
Faraday Future Intelligent Electric Inc (FFAI) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Community Health Systems, Inc Inc. (CYH) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Checking in on BioNTech SE ADR (BNTX) after recent insiders movement - knoxdaily.com
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - The Motley Fool
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Yahoo Finance
BioNTech SE ADR [BNTX] Shares Jump Approximately 32.28% Over the Year - knoxdaily.com
Today’s watch list includes BioNTech SE ADR (NASDAQ:BNTX) stock - uspostnews.com
AMKOR Technology Inc [AMKR] Records 200-Day SMA of $26.99 - knoxdaily.com
Fluence Energy Inc [FLNC] Officer makes an insider purchase of 78,258 shares worth 0.29 million. - knoxdaily.com
Immunovant Inc [IMVT] Records 50-Day SMA of $18.03 - knoxdaily.com
It makes sense and dollars to buy BioNTech SE ADR (BNTX) stock - Sete News
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains? - Yahoo Finance
BioNTech Surges On Summit's Coattails. But Can They Take On Merck? - Investor's Business Daily
Hewlett Packard Enterprise Co (HPE): What Are The Positives? - Marketing Sentinel
MARA Holdings Inc (MARA) Is A Buy Stock For Small Caps – Analysts - Marketing Sentinel
Stocks With Rising Relative Strength: BioNTech ADR - Investor's Business Daily
BioNTech, Pfizer report good news from vaccine trial - Morningstar
Century Aluminum Co [CENX] Stock sold by Insider Hoffman Robert F for $0.1 million - knoxdaily.com
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? - Yahoo Finance
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - Yahoo Finance
Pfizer Stock Falls To New 52-Week Low: Should You Buy The Dip? - Barchart.com
CureVac’s amended patent upheld by European Patent Office - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Earnings Call: Oncology Growth Amidst Challenges - TipRanks
BioNTech’s 2024 Earnings Highlight Oncology Focus - TipRanks
BioNTech Earnings: 2025 Guidance Disappoints, Fair Value Lowered - Morningstar
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
Jefferies maintains BioNTech stock Buy rating, $149 target - Investing.com India
BioNTech Q4 earnings beat, but stock falls 3% on weak 2025 outlook - Investing.com
Earnings call transcript: BioNTech beats Q4 2024 expectations, stock dips - Investing.com
US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory - Benzinga
BioNTech reports Q4 EPS EUR 1.08 vs. EUR 1.88 last year - TipRanks
Here's Why Moderna Stock Soared 16% On Wednesday - Barchart
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):